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Lois A. Killewich, MD, PhD,a Demidmaa Tuvdendorj, MD, PhD,a John Bahadorani, BA,a
Glenn C. Hunter, MD,a and Robert R. Wolfe, PhD,b Galveston, Tex; and Little Rock, Ark
Objective: Older patients with peripheral arterial disease (PAD) and intermittent claudication have impaired walking
ability resulting from reduced lower extremity blood flow. Evidence suggests that leg muscle abnormalities may also
contribute to walking intolerance in claudicants. In healthy elderly people, leg muscle protein synthesis can be augmented
by nutritional supplementation with amino acids; preliminary data suggest that this increases muscle mass, walking
ability, and functional status. In this study, we investigated whether amino acid supplementation would improve leg
muscle protein synthesis in elderly PAD subjects, given that reduced leg blood flowmight restrict the availability of amino
acids to muscle.
Methods: Two groups participated in the study: a group of 11 claudicants (mean age, 62 years; mean ankle-brachial index,
0.62; 46% male) and a group of 9 age- and sex-matched healthy controls (mean ankle-brachial index, 1.1). Both groups
underwentmeasurement of leg blood flow by using strain gauge plethysmography, as well as measurement of baseline and
amino acid–stimulated protein synthesis in leg muscle. Protein synthesis was quantified from calf muscle biopsy samples
by measurement of the fractional synthetic rate (FSR) of protein, by using the incorporation of the stable isotope
L-[ring-2H5]-phenylalanine into muscle protein. Total protein was extracted from muscle samples, and gas chromatog-
raphy/mass spectroscopy methodology was used to measure incorporation rates. After measurement of basal FSR, all
subjects were given an oral drink of 15 g of essential amino acids, and the measurements of FSR were repeated. Data are
expressed as mean  SD; statistical analysis of differences between the two groups (with and without amino acid
supplementation) was performed by using analysis of variance with repeated measures.
Results: Calf blood flow was reduced in the PAD subjects compared with controls (1.44  0.53 mL/min per 100 mg of
tissue vs 2.40  0.57 mL/min per 100 mg of tissue; P  .005; t test). FSR in the basal state was equivalent between the
two groups (healthy, 0.060%  0.025% per hour; PAD, 0.061%  0.029% per hour; P  .97). Equivalent increases (P <
.05) occurred in both groups in response to oral amino acid supplementation (healthy, 0.087% 0.012% per hour; PAD,
0.104%  0.041% per hour; P > .05; analysis of variance).
Conclusions: Despite reduced leg blood flow, elderly PAD patients synthesize calf muscle protein in the basal state in a
fashion similar to that in healthy elderly people. More importantly, administration of exogenous amino acids produces a
significant increase in protein synthesis in these patients that is also equivalent to that in healthy elderly people. Our goal
is to use these results as the basis for an intervention study to determine whether long-term oral amino acids, by
augmenting calf muscle protein synthesis, increase calf muscle mass, walking ability, and functional status in elderly
claudicants. ( J Vasc Surg 2007;45:554-60.)Intermittent claudication (IC), the first clinical stage of
peripheral arterial disease (PAD), affects 5% to 10% of the
US population older than 55 years, and its prevalence
increases with age to affect approximately 20% of those
older than 70 years.1 It is estimated1 that more than 10
million individuals will be affected by this progressive de-
bilitating disease by the year 2015.
The primary pathophysiology of IC is a reduction in
blood flow to leg skeletal muscle; the reduction results from
occlusive disease of lower extremity arteries. Therapy for IC
has therefore targeted increasing blood flow or improving
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554muscle function. Current nonoperative therapies, such as
exercise rehabilitation2 and the pharmacologic agent
cilostazol,3 primarily treat muscle function. More invasive
treatments, such as angioplasty,4 stenting,4 and surgical
bypass,5 increase blood flow. Although all are effective to
varying degrees, none is universally applicable, and treat-
ment of the reduced functional status and quality of life in
PAD patients remains a major challenge.
Previously, our group has demonstrated that nutri-
tional supplementation with oral essential amino acids
(AAs) will improve leg skeletal muscle protein synthesis,
mass, and functional status in healthy elderly individuals.6-9
A logical extension of this work is assessment of whether
AA supplementation would also improve muscle mass and
functional status in older claudicants. However, previous
studies have shown that stimulation of leg muscle protein
synthesis by AAs is dependent on the delivery of AA to
muscle, which is in turn a function of leg blood flow.10
Because older claudicants by definition experience reduced
leg blood flow, AA administration might not be effective in
these patients. The hypothesis of this study was that base-
line postabsorptive calf muscle protein synthesis in elderly
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elderly people and that stimulation of protein synthesis by
exogenous AAs is also impaired.
METHODS
Subjects
Eleven older claudicants and nine healthy elderly vol-
unteers participated in this study. Claudicants were re-
cruited from the Vascular Surgery Clinics at the University
of Texas Medical Branch (UTMB) and were identified by
typical symptoms of lower extremity muscle pain brought
on by walking and relieved by rest, together with resting
Doppler-derived ankle-brachial indices (ABI) of 0.9 or
lower. Healthy control subjects were recruited from the
Sealy Center for Aging volunteer registry at UTMB. Exclu-
sion criteria included current participation in a muscle-
strengthening program, currently on a weight-loss diet,
recent (within 6 months) ingestion of anabolic steroids or
corticosteroids, or recent (within 6 months) lower extrem-
ity revascularization. All subjects were fully informed about
the purpose and procedures of the study and provided
written consent according to the guidelines established by
the Institutional Review Board at UTMB, which approved
the protocol before initiation of the study.
Experimental protocol
Overview. Calf (gastrocnemius) muscle protein syn-
thesis was quantified by measuring the incorporation of a
stable isotope of the essential AA (EAA) phenylalanine into
the muscle protein by using gas chromatography/mass
spectrometry methodology.6-10 Muscle samples were ob-
tained by biopsy. To ensure that a steady state with respect
to the enrichment of the stable isotope was maintained,
enrichments were measured on blood samples obtained
from an arterialized hand vein throughout the proto-
col.11,12 Protein synthesis was measured in the basal, post-
absorptive state and after administration of an oral bolus
of EAAs.
Protocol. The experimental protocol (Fig 1) was per-
formed in the General Clinical Research Center at UTMB.
All study participants were instructed to maintain their
normal diet in the weeks preceding the study. Participants
were admitted to the General Clinical Research Center the
night before each study, underwent an overnight fast, and
were allowed only water on the day of the study.
On the morning of the study, polyethylene catheters
were inserted into a forearm vein for infusion of L-[ring-
2H5]-phenylalanine (Cambridge Isotope, Andover, Mass)
and into the contralateral upper extremity dorsal hand vein
for arterialized blood sampling. A blood sample was ob-
tained for measurement of the background AA enrichment.
A primed continuous infusion (priming dose, 2 mol/kg;
infusion rate, 0.05 mol · kg1 · min1) of labeled phenyl-
alanine was then initiated through the forearm vein cathe-
ter and continued throughout the study. Before infusion, it
was dissolved in 0.9% sterile saline and filtered through a
2-m filter. Venous blood collected from the dorsal handvein was “arterialized” by wrapping the hand in a heating
blanket.11,12 Blood samples were collected from this cath-
eter hourly throughout the study to establish the presence
of an arterial steady state of phenylalanine enrichment.
Arterialization of the venous blood was confirmed by
hourly blood gas analysis.12
Muscle biopsies (50 mg) were obtained from the gas-
trocnemius muscle of one leg of each participant under
sterile conditions and local anesthesia (1% lidocaine with
added 8.4% sodium bicarbonate mixed 1:10) by using a
5-mmBergstrom biopsy needle. After administration of the
local anesthetic, an incision (1-2 mm) through the skin and
superficial fascia was created; all biopsy samples were ob-
tained from the same incision site, but at 180° to each other
and 2 to 3 mm apart to minimize inflammatory interfer-
ence. Biopsies were performed at 120, 240, and 480 min-
utes after initiation of the stable isotope infusion (Fig 1).
After each biopsy, muscle samples were rinsed with sterile
saline, blotted dry, immediately frozen in liquid nitrogen,
and stored at 80°C for later analysis.
The basal, postabsorptive rate of gastrocnemius protein
synthesis was measured by using the first twomuscle biopsy
samples by quantification of the fractional synthesis rate
(see below). After the second biopsy, each participant in-
gested an oral mixture of 15 g of EAAs (Table I) dissolved
in a noncaffeinated, noncaloric soft drink. The composition
of the EAA drink was developed to approximate the distri-
bution of EAA in skeletal muscle and the amount required
to produce an increase in the intracellular concentrations of
the EAAs in relation to their respective contributions to
muscle protein synthesis.9,13,14 The underlying assumption
in this stable isotope methodology is that an isotopic steady
state is achieved and maintained.15 Therefore, on the basis of
previous studies, it was determined that while using a constant
infusion of L-[ring -2H5]-phenylalanine (0.05 mol · kg
1 ·
min1), an additional 0.186 g of L-[ring -2H5]-phenylalanine
should be added to the EAA drink to maintain the isotopic
enrichment (tracer/tracee ratio) in the blood at approxi-
mately 0.08 (isotopic steady state).9,13,14 The EAA-stimu-
lated rate of muscle protein synthesis was calculated by
using the time interval between the second and third mus-
cle biopsies (Fig 1).
After the final muscle biopsy, calf blood flow was mea-
Fig 1. Experimental protocol. EAA, Essential amino acid drink,
administered as an oral bolus; Strain gauge, measurement of calf
blood flow by strain gauge plethysmography; Hr, hour of study;
Blood, blood sampling from arterialized dorsal hand vein; Muscle,
gastrocnemius muscle biopsy.sured by using strain gauge plethysmography in accordance
JOURNAL OF VASCULAR SURGERY
March 2007556 Killewich et alwith previously described methods.16,17 Briefly, the ple-
thysmographic examination was performed at room tem-
perature and was performed on both legs simultaneously
with the subject in the supine position. Mercury-in-silastic
strain gauges (Hokanson, Bellevue, Wash) were placed
around the calf muscle at the point of greatest circumfer-
ence,17 and cuff inflators were used to rapidly inflate and
deflate blood pressure cuffs placed around the thighs and
ankles bilaterally. The blood flow output signals were trans-
mitted to a recorder. Calf blood flow values were expressed
as milliliters per minute per 100mL of leg tissue volume. At
the end of the protocol, peripheral lines were removed;
subjects were provided with a meal and were monitored for
1 to 2 hours before discharge.
Analytical methods
Blood. Arterialized blood samples from the retro-
grade catheter in the dorsal hand vein were collected for
PO2 measurement and serum AA enrichment. PO2 was
measured by a Rapidpoint 405 System (Bayer HealthCare,
Clayton, NC) in the Department of Pathology, UTMB.
Blood for AA enrichment was immediately mixed in pre-
weighed tubes containing 15% sulfosalicylic acid solution.
Samples were reweighed and centrifuged, and the subse-
quent supernatant was removed and frozen at 80°C.
Upon thawing, blood AAs were extracted from 500 L of
supernatant by cation exchange chromatography (Dowex
AG 50W-8X; 100-200 mesh H form; Bio-Rad Laborato-
ries, Richmond, Calif) and dried under a vacuum (Savant
Instruments, Farmingdale, NY). Phenylalanine enrichments
and concentrationswere determined on the tert-butyldimeth-
ylsilyl derivative by using gas chromatography/mass spec-
trometry (GC-MSHPmodel 5989; Hewlett-Packard, Palo
Alto, Calif) with electron impact ionization. Ions 336 and
341 were monitored.18
Muscle. Twenty to twenty-five milligrams of muscle
was homogenized in 800 L of 10% perchloric acid. The
free intracellular enrichment of phenylalanine was mea-
sured on the supernatant obtained after tissue homogeni-
zation and centrifugation. The bound phenylalanine (that
incorporated into muscle protein) was measured from the
pellet obtained after centrifugation. The pellet was washed
and dried, and the proteins were hydrolyzed in 6 N HCl at
110°C for 24 hours. The hydrolysate was processed in the
Table I. Composition of the essential amino acid drink
Amino acid Grams % Total
Histidine 1.64 10.9
Isoleucine 1.56 10.4
Leucine 2.79 18.6
Lysine 2.33 15.5
Methionine 0.46 3.1
Phenylalanine 2.33 15.5
Threonine 2.20 14.7
Valine 1.73 11.5
Total 15.00 100same fashion as the blood samples, and the phenylalanineenrichment was measured by gas chromatography/mass
spectrometry by using chemical ionization as described by
Calder et al.18
Protein synthesis calculation
Gastrocnemius protein synthesis was quantified by cal-
culation of the fractional synthetic rate (FSR) of total
muscle protein, by measuring the incorporation rate of the
stable isotope of phenylalanine (L-[ring-2H5]-phenylalanine)
into muscle protein. Muscle FSR was calculated by dividing
the increment in enrichment in the protein-bound phenyl-
alanine tracer/tracee ratio by the enrichment in the free
intracellular phenylalanine tracer/tracee ratio in the basal
period and after oral EAA administration6,8 (Fig 2).
Sample size calculation
The sample size was calculated by anticipating a change
of 50% or greater in all measurements, on the basis of
previous studies performed by our group.6-10 These studies
demonstrated coefficients of variation for changes in vari-
ous parameters of protein synthesis in the range of 15% to
30%. Therefore, the sample size was calculated on the basis
of the number of subjects required to demonstrate a differ-
ence in a parameter with a coefficient of variation of 30%.
On the basis of the assumption of a type I error of 0.05 and
a power of  of 0.8, we calculated that eight subjects per
group should be sufficient to detect a 50% difference.
Statistical analysis
Differences between the two study groups were ana-
lyzed by using the t test assuming equal variances and 2
analysis. Comparison of the rates of protein synthesis be-
tween the two groups before and after EAA ingestion were
performed by using analysis of variance with repeated mea-
Fig 2. Calculation of fractional synthetic rate of total gastrocne-
mius muscle protein (FSR). Ep, Change in protein-bound phe-
nylalanine enrichment (tracer/tracee ratio); EM(1), free intracellu-
lar phenylalanine enrichment at first biopsy;EM(2), free intracellular
phenylalanine enrichment at second biopsy; t, time interval be-
tween biopsies (minutes). Results are expressed as percentage per
hour, multiplying by the factors 60 minutes per hour and 100.sures. Differences were considered significant if P  .05.
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PAD and control groups were matched with respect to
age and sex (Table II). Hypertension, diabetes mellitus,
dyslipidemia, coronary artery disease, and smoking (ever)
were more prevalent in the claudicant group (Table II). Calf
blood flow and ABI were significantly reduced in the claudi-
cant group compared with the control group (Table III).
A steady state with regard to phenylalanine enrichment
was achieved within 60 minutes of initiation of the labeled
phenylalanine infusion and was maintained throughout the
study period. Confirmation of arterialization of the venous
blood was obtained by measurement of PO2; the mean PO2
was 59  6 mm Hg (Fig 3).
FSR in the basal state was not significantly different
between groups (healthy, 0.060%  0.025% per hour;
PAD, 0.061%  0.029% per hour; P 	 .97). Significant
increases (P .05) occurred in both groups in response to
oral AA supplementation (healthy, 0.087%  0.012% per
hour; PAD, 0.104%  0.041% per hour); the increases
between the two groups were equivalent (P
 .05; analysis
of variance; Fig 4).
DISCUSSION
The most important finding of this study was that
despite reduced calf blood flow, older claudicants synthe-
size calf muscle protein in a fashion similar to that in healthy
elderly people and are able to respond to a single oral bolus
of EAAs in a similar manner. The next step will be to
determine whether longer-term AA administration will im-
prove leg muscle mass and strength in claudicants and
Table II. Subject demographics
Variable
PAD
(n 	 11)
Control
(n 	 9) P value
Age, y (mean  SD) 62.4  6.3 63.7  9.4 .71*
% Male 45.5 55.6 .88†
% With hypertension 100 44.4 .04†
% With diabetes mellitus 54.5 0 .01†
% With dyslipidemia 54.5 0 .01†
% With coronary artery disease 36.4 11.1 .05†
Smoking (ever) (%) 90.9 33 .03†
PAD, Peripheral arterial disease.
*By t test.
†By 2 test.
Table III. Leg characteristics
Variable
PAD
(n 	 11)
Control
(n 	 9) P value
Ankle-brachial index 0.62  0.16 1.10  0.25 .004*
Calf blood flow (mL/min
per 100-mL tissue
volume) 1.44  0.53 2.40  0.57 .005*
PAD, Peripheral arterial disease.
*By t test.whether this in turn will improve walking ability and func-tional status. Preliminary data obtained by our group sug-
gest that this is possible for healthy elderly people. Sixteen
weeks of oral AA supplementation (15 g of EAAs adminis-
tered twice a day) to these individuals resulted in increased
leg muscle mass, quantified by magnetic resonance imag-
ing, and leg strength, quantified as increased one-repetition
maximum, as well as improvements in functional status
measured by summary performance scores (unpublished
data).
Previous studies addressing nutritional supplements in
the elderly have produced mixed results. Fiatarone et al19
administered multinutrient supplements to 100 frail nurs-
ing home residents over a 10 week period and found no
effects on muscle strength, thigh muscle cross-sectional
area, gait velocity, or stair-climbing ability. Milne et al20
performed a meta-analysis of 55 randomized controlled
trials (9187 subjects) addressing oral protein and energy
supplementation in the elderly and found that supplements
decreased mortality and complication rates for undernour-
ished hospitalized elderly patients but did not seem to have
any benefits on functional status or in well-nourished sub-
jects. The differences between these findings and ours may
Fig 3. Steady state of L-[ring-2H5]-phenylalanine (Phe) enrich-
ment measured from an arterialized (PO2) hand vein.
Fig 4. Fractional synthetic rate of gastrocnemius muscle protein
(percentage per hour) in the basal, postabsorptive state and after
ingestion of 15 g of oral amino acids (AA-stimulated) in healthy
elderly (control) and peripheral arterial disease (PAD) patients.be related to the amount and composition of the protein in
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such as carbohydrates. Evidence exists that the inclusion of
carbohydrates in nutritional supplements for the elderly is
not beneficial21 and may actually reduce the benefits of AAs
alone.6,7 Additionally, previous studies have shown that
elderly subjects who take supplements reduce their normal
dietary intake correspondingly, meaning that they do not
experience increased total daily energy intake.19 Hence, to
be effective, a nutritional supplement for the elderly should
stimulate muscle anabolism more efficiently than regular
food, so that if normal intake is reduced, total energy intake
is still increased. In regard to this, we have found that the
improvements elderly subjects experience from AA supple-
ments are associated with EAAs; non-EAAs are truly non-
essential in terms of beneficial effects on muscle.6 Tradi-
tional protein supplements contain a large proportion of
non-EAAs,6 and this may also detract from their overall
benefit.
Studies of nutritional supplements in patients with
PAD have been very limited and have also produced mixed
results. A meta-analysis of omega-3 fatty acid administra-
tion in claudicants demonstrated no benefits on walking
distances or ABIs.22 A pilot study demonstrated a trend
toward an increase in walking distance with L-arginine (the
precursor of nitric oxide and a stimulator of endothelium-
dependent vasodilation) in 20 claudicants.23 A carbohy-
drate supplement increased walking times in a small group
(n 	 8) of claudicants already participating in an exercise
rehabilitation program.24 This paucity of data provides
further support for additional trials of nutritional supple-
ments in the treatment of PAD.
Originally we hypothesized that the reduced blood
flow found in patients with IC might restrict the delivery of
AAs to calf muscle and that this would reduce both basal
and AA-stimulated calf muscle protein synthesis. A previous
study performed by our group demonstrated that muscle
protein synthesis in healthy subjects was regulated by the
concentration of AAs in blood rather than by the intracel-
lular concentration.10 In another study, changes in leg
muscle protein synthesis were directly and significantly
correlated with changes in leg blood flow in healthy young
subjects treated with insulin.25 However, Short et al26
found that although administration of prednisone de-
creased leg blood flow by 25% in healthy young people,
there was no effect on leg muscle protein synthesis. We
speculate that although increasing leg blood flow may
increase protein synthesis, the reduction in flow observed in
patients with claudication (40% in this study) is not of
sufficient magnitude to restrict the availability of AAs to calf
muscle to a degree necessary to reduce protein synthesis.
Indeed, preliminary data obtained by our group in a rabbit
model showed that reduction of leg blood flow by one third
by using angioplasty balloons had no effect on either basal
or AA-stimulated leg muscle protein synthesis (unpub-
lished data).
These findings have significant implications for the
treatment of IC. At this time, the options for noninvasive
treatment are limited. Exercise rehabilitation, althougheffective,2 is not applicable to many patients who cannot
exercise sufficiently to improve walking ability because of
comorbidities such as coronary artery disease and osteoar-
thritis. Studies have shown that home exercise programs are
much less effective than supervised programs,27 yet many
patients are unwilling or unable to travel to centers for
supervised exercise several times per week. Only one med-
ication, cilostazol, is currently approved by the US Food
and Drug Administration for the treatment of claudication.
Side effects, cost, and contraindications prevent its use in
many patients.3 Invasive procedures such as angioplasty
and stenting have produced mixed results regarding im-
provements in functional capacity and quality of life in
claudicants,4 and surgical bypass is unsafe in many pa-
tients.5 There is a need for more widely applicable, effective
treatments to improve functional status and quality of life in
patients with this common disease. It is our hope that AA
supplementation may ultimately prove to be one of these
treatments.
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Dr RonaldWebb (Oakland, Calif): First of all, I would like to
thank the program committee for askingme to review this paper. It
forced me to review a little bit of biochemistry. Second of all, I
would like to thank Drs Dilley and DeLaria for having this meeting
at what I think has been an exceptionally nice venue, and I would
also like to thank Dr Killewich for communicating with me by
e-mail with this paper several weeks ago. It is also interesting this is
the first day in Washington for peripheral arterial disease to discuss
a paper with regards to amino acids and peripheral arterial disease.
There are really three things that have had level I evidence that
improved claudication distance, and one has been smoking cessa-
tion, one has been supervised exercise, and the third has been
Pletal.
There are other drugs that we are using now in the office that
I think help us with the management of the claudicant. The statin
drugs of interest have been shown to actually lower the C-reactive
protein which you know is an inflammatory index of carotid artery
disease. Plavix has improved the claudication distance with which I
was not aware. The (CAPRI) study actually shows a stronger
benefit in those people with peripheral vascular disease than it does
in preventing TIA. I think most of us now are also starting patients
on ACE inhibitors and beta-blockers.
The question this paper has asked is, will amino acid supple-
ments help the claudicant? I think this is an interesting paper. I ride
bicycles a lot. There is a cult amongst bicycle riders. They have
recovery drinks they take. I ride with bicycle riders who actually
take insulin injections to speed up the entry of amino acids into
their mitochondria. I think Floyd Landis is a Southern Californian
and Barry Bonds is a Northern California.
There are 12 nonessential amino acids, which can be manu-
factured from the eight dietary essential amino acids inside the
body. There are three branch change amino acids, which arecycle is interesting. This is anaerobic muscle metabolism. After the
liver and the muscle utilize glucose, they begin to use amino acids.
The byproducts of this, lactate and pyruvate, probably cause a lot
of the muscle pain that we have when we experience claudication,
but there are also other side effects of that.
Carnitine is an interesting protein because it facilitates the
rapid exchange of these amino acids into the mitochondria. Car-
nitine has been used in drinks in Europe to try to improve claudi-
cation. Vanderbilt studied an intradialytic parenteral nutrition
where they put people on dialysis on amino acid infusions during
dialysis and have demonstrated increased strength, walking ability
and just well-being after doing this during this opportunity three
times a week on 4 hours of dialysis. I did find one study that
demonstrated insulin does not stimulate protein synthesis within
the muscle. There is evidence that a continuous infusion of phe-
nylalanine improves muscle protein synthesis after endurance run-
ning.
Having said all this, claudication is not just simply a reduction
in blood flow to themuscle mass. There are events that occur at the
moment of claudication which involve endothelial dysfunction.
There are free radicals produced. There are acute-phase proteins
produced. There is another factor called cellular adhesion mole-
cules. There are differences in nitric oxide availability, which is also
affected by arginine levels. Acetyl-carnitine is a breakdown of
carnitine, which increases dramatically at the moment of claudica-
tion that may be causing some of the muscle pain that we get
during claudication, and then, of course, there is lactic acid.
In addition, claudication is probably more importantly a
marker of other symptoms of peripheral vascular disease or periph-
eral arterial disease. It has been suggested that 40% of people die or
have a stroke within 5 years after having had claudication found as
a marker, and one study said even as high as 60% will have coronary
artery disease within 5 years.
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March 2007560 DiscussionThis paper does seem to show that nutritional supplementa-
tion can increase the muscle mass of claudicants. However, this
paper does not document that the pain of claudication or the
distance of claudication improved with nutritional supplementa-
tion. Will Hiatt at the University of Colorado has shown an
increase in treadmill distance after giving 2 grams of carnitine twice
daily orally.
My questions to the author are, one, what mixture of essential
acids and nonessential amino acids do you feel could improve the
exercise tolerance of a claudicant? Number two, why did you
choose phenylalanine rather than leucine, arginine, or carnitine for
this study? And what type of study would you design to prove you
could increase claudication distance—a 6-minute walk test, gaited
treadmill exercise, peak blood flow with plethysmography, or
Doppler indices?
I appreciate having the opportunity to discuss this paper.
Dr Lois Killewich: Thank you very much, Dr Webb, for your
comments. I guess I have an advantage here; the questions are
right here up where I can see them. What mixture of essential and
nonessential amino acids do you feel could improve the exercise
tolerance of claudicants? Well interestingly I did not really go over
it in my paper, but the work on essential amino acids was started by
a large group of physiologists in Galveston headed by Dr Wolfe,
whom you alluded to in your comments. They have studied in the
past essential versus nonessential amino acids, and they found that
the nonessential amino acids, at least in healthy elderly, had no
benefit. That is why in my study I have used essential amino acids
only and the studies we plan to do in the future will be using only
essential amino acids.
Why we chose phenylalanine rather than a different stable
isotope basically has to do with the cost, the availability, and the
fact that, for example, the lucine stable isotope is oxidized in
muscle, and so if you are going to use that as your tracer for protein
synthesis, you have to do a lot of additional calculations and
measurements in order to account for the oxidation. It is really just
an ease of use of the isotope.
And what type of study would I design to prove that I could
increase claudication distance? Well, the study that we are starting
now, we are going to give amino acid supplements to claudicants
for a 16-week period and our end points are going to include both
treadmill testing and the 6-minute walk test. The 6-minute walk
test is a very simple test of claudication, which actually was devel-
oped by Andy (Gardner), and it involves having a patient walk in a
hallway between cones. There is no treadmill, no graded treadmill,
or constant load treadmill, and it has been validated in the sense
that it is thought to reflect walking during daily activities of living
more appropriately. We will be using that test. We will be using
treadmill testing, and we will also be using various measurements
of functional capacity.
Dr George Andros (Encino, Calif): I had a few questions.
Isn’t this basically a pharmacology investigation?
Dr Killewich: Okay.
Dr Andros: And in most pharmacology investigations there
are at least two essential criteria for the assessment of the drug; one
is a time curve for the appearance of the effect, and a second is a
dose-response curve. Have you inquired into these?
Several years ago, we were involved with the use of a magnetic
resonance flowmetry technique and we had a lengthy discussion
with Gene Strandness about whether or not blood flow at rest in
claudicants is increased or decreased or the same, and our data
showed that blood flow as compared to calf plethysmography was
decreased in claudicants at rest. He felt that it was not decreased,
and we had many discussions on this. So, there is a fundamental
question here: is blood flow in claudicants decreased or normal?
Then there is the other question of biopsy distortion. In my
previous life as a biophysicist, I did many animal studies on biopsydistortion of blood flow and we found that is a significant effect on
blood flow as you do serial biopsies of muscle structure.
The final point that I had was that I think there is a missing
control group. You have a control group that is given phenylala-
nine and a normal group. Do you have a control group in which
you have claudicants with their presumed reduced blood flow who
received phenylalanine and those who received some other nones-
sential amino acid or some other control group within the group
that you are studying so that the control group I believe should be
two different claudicant groups rather than a claudicant and a
control group.
DrKillewich:Thank you very much, Dr Andros. Yes, we have
done the time study and also the dose-response study, and we have
done those at a couple different doses of amino acids. We did it at
8 grams of essential amino acids. We did it at 15 grams. We have
also done nonessential amino acids and amino acid and carbohy-
drate combinations. Yes, we did do those and we found that the
most benefit was associated with the 15-gram essential amino acid
in this particular time duration.
As far as is blood flow reduced at rest, I do not really know the
answer to that question other than what we did in this study and
that is we measured calf blood flow using strain gauge and that is a
pretty standard technique which is used in the literature. A lot of
studies have used that technique and so all I can say is that we did
find it was reduced at rest in these patients.
As far as biopsy distortion of blood flow, I think the key point
there is that we measured blood flow at the end of the protocol
after we had already done three muscle biopsies and so you could
make the argument that—I think it is what you are saying—the
biopsies distorted the blood flow measurement which we did after
the biopsies, but in fact, when we started doing this we were doing
blood flow measurements at the beginning of the protocol and we
did them twice, once at the beginning and once at the end. We did
not find any difference and so we stopped doing them at the
beginning because it was too cumbersome for the overall protocol.
Finally, I would have to say that you are correct; we do not
have the control group where we gave them a different amino acid.
Dr Niren Angle (San Diego, Calif): Beautiful paper. I have a
quick question for you. If you look in the exercise physiology
literature there is a fair amount of data that says that most protein
does not matter. It is the branch chain amino acid supplementa-
tion, the isolucine, the valine, and the lucine, and I know there is a
fair amount of controversy about that, but could you comment on
using just branch chain amino acids instead of essential.
Number two, have you entertained doing this with having
them do resistance training or exercising and then supplementing
them within a few hours or within an hour of exercise because that
seems to increase muscle mass much more than the standard
supplementation of protein at any variable time during the day.
Thank you.
Dr Killewich: Thank you very much. I cannot say that we
have actually studied branch chain amino acids and so I cannot say
whether they would have the same benefit that our particular
formulation of essential amino acids has but you certainly have a
valid point there.
As far as using exercise training, in particular endurance train-
ing, as well as amino acids; yes, we have contemplated doing that.
We have done some studies on that, not in claudicants, and we
would like to do that in the future. Other investigators in
Dr Wolfe’s group have shown that the combination of endur-
ance exercise and oral amino acids will actually improve your
muscle protein synthesis and your strength greater than just
amino acids alone. Needless to say, the question is always raised
with claudicants as to how much they can exercise, but I chose
amino acids initially because I felt that this might be more
widely applicable.
